When Research Is Best Therapy
Siris, Ethel S.
Kemeny, M. Margaret
Hastings Center Report. 1988 Apr/May; 18(2): 24-26.
A case study is presented in which a physician must decide whether to ask a renal cell carcinoma patient, who has declined treatment unless it would improve his quality of life or extend his period of survival, to participate in a study comparing a standard progestational agent (Depo-provera) with an otherwise unavailable drug (gamma-interferon) which offers the only promising treatment for his disease. Two commentaries weigh the moral obligations of the physician, the patient, and the drug company in a circumstance where the patient has the right to withdraw from the study if he is randomly chosen to receive the less effective drug. (KIE abstract)
Alternatives; Cancer; Case Studies; Consent; Disclosure; Disease; Drug Industry; Drugs; Human Experimentation; Industry; Informed Consent; Life; Moral Obligations; Patients; Physicians; Prognosis; Quality of Life; Random Selection; Research; Research Design; Research Subjects; Risks and Benefits; Terminally Ill; Therapeutic Research; Toxicity;
Showing items related by title, author, creator and subject.